← Leaderboards
Susanna Naggie
Durham Va Medical Center
$60,981,544
Attributed
$171,159,012
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $116.4M · FY2011–25$200M$150M$100M$50M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$179,091,301 · 9
VA$0 · 1
By mechanism
U24$136,143,799 · 1
UL1$17,117,880 · 1
UM1$9,890,205 · 1
P30$7,932,289 · 1
U01$3,411,692 · 1
R01$1,961,760 · 1
Top collaborators
- Ashutosh Chilkoti4 shared
- Michael David Lynch4 shared
- Cynthia A Moylan4 shared
- Daniel K Benjamin3 shared
- Adrian Hernandez3 shared
- Georgia D Tomaras3 shared
- Jennifer S Li2 shared
- James O. Mcnamara2 shared
Others in their field
Top investigators on “Persons”
- Wafaa M. El-Sadr · Columbia University Health Sciences$688,439,560
- Lawrence Corey · Fred Hutchinson Cancer Center$646,462,796
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- David R. Weir · University Of Michigan At Ann Arbor$386,183,647
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$377,922,183
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$265,384,316
Research focus
PersonsUnited StatesEnsureBaseViralEventCohortInfectionFutureInnovationValidationPathogenesisCessation Of LifeProgramsCollaborationsResearch PersonnelResponseLiverLiver DiseasesLipidsMetabolicHiv InfectionsHepatitis C VirusCo-Infection
Grant awards (28)
CTSA UM1 at Duke University$9,890,205
UM1 · FY2025 · TR · contact PI
Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST)$3,411,692
U01 · FY2025 · AI · contact PI
Center for AIDS Research$2,883,369
P30 · FY2025 · AI
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2025 · VA · contact PI
Centers for AIDS Research (CFAR)$2,250,000
P30 · FY2024 · AI
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2024 · VA · contact PI
Duke CTSA$7,336,234
UL1 · FY2023 · TR
Centers for AIDS Research (CFAR)$2,798,920
P30 · FY2023 · AI
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2023 · VA · contact PI
ACTIV-6$20,600,000
U24 · FY2022 · TR
Duke CTSA$9,781,646
UL1 · FY2022 · TR
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy$0
I01 · FY2022 · VA · contact PI
ACTIV-6$77,049,200
U24 · FY2021 · TR
ACTIV 6$38,494,599
U24 · FY2021 · TR
Rapid diagnosis and quantification of HIV by direct capture, labelling and detection of individual virions$444,310
R61 · FY2021 · AI
Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV$391,834
R01 · FY2021 · DK · contact PI
Rapid diagnosis and quantification of HIV by direct capture, labelling and detection of individual virions$444,310
R61 · FY2020 · AI
Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV$391,834
R01 · FY2020 · DK · contact PI
Rapid diagnosis and quantification of HIV by direct capture, labelling and detection of individual virions$287,713
R61 · FY2020 · AI
Rapid diagnosis and quantification of HIV by direct capture, labelling and detection of individual virions$444,310
R61 · FY2019 · AI
Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV$391,834
R01 · FY2019 · DK · contact PI
Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV$386,049
R01 · FY2018 · DK · contact PI
Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV$400,209
R01 · FY2017 · DK · contact PI
Systems Biology Approaches for Predicting Cardiometabolic Risk in Persons Living with HIV$658,233
R56 · FY2015 · HL
Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients$88,700
K23 · FY2014 · AI · contact PI
Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients$88,700
K23 · FY2013 · AI · contact PI
Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients$88,700
K23 · FY2012 · AI · contact PI
Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients$88,700
K23 · FY2011 · AI · contact PI